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PEMBANGUNAN ASAI PENGESANAN PROTEIN 16 kDa DARIPADA 
Mycobacterium tuberculosis MENGGUNAKAN UJIAN 
IMUNOKROMATOGRAFI 
 
ABSTRAK 
 
Mycobacterium tuberculosis (Mtb) adalah patogen yang boleh menyebabkan 
penyakit tuberculosis (TB). Penyakit TB yang berjangkit ini masih kekal menjadi 
masalah kesihatan yang utama di seluruh dunia. Penyakit ini ditular melalui 
pernafasan atau titisan udara yang mengandungi Mtb yang terhasil daripada pesakit 
TB. Pengesanan awal penyakit ini adalah penting bagi mengelakkan pemindahan 
penyakit tersebut kepada orang lain yang berada rapat dengan pesakit. Sehingga hari 
ini, belum ada lagi ujian diagnostik yang mudah, cepat, sensitif dan spesifik untuk 
penyakit TB. Kajian-kajian terdahulu telah menunjukkan antigen Mtb 16 kDa 
mempunyai potensi dalam pendiagnosian TB. Dalam kajian ini, kaedah asai 
imunokromatografi aliran melintang (ICT) dipstik terhadap antigen 16 kDa telah 
dibangunkan dan dinilai sebagai kaedah yang cepat dan berpotensi untuk 
mendiagnos jangkitan TB. Antibodi monoklon anti-16 kDa telah dioptimumkan 
sebagai antibodi penambat dan antibodi pengesan pada pelantar ICT. Parameter 
untuk garisan kawalan, bahan penebat, larutan penimbal ujian, pengalas konjugat dan 
pengalas sampel telah dioptimumkan sebelum prototaip dipstik TB-antigen ICT 
dilengkapkan. Kajian sensitiviti terhadap prototaip dipstik TB-antigen ICT 
menunjukkan dipstik tersebut mampu mengesan antigen 16 kDa yang tulen serendah 
125 ng. Walau bagaimanapun, kajian spesifisiti prototaip tidak dapat dimuktamadkan 
kerana kaedah yang digunakan untuk penyediaan sampel memerlukan kajian lanjut. 
Hasil daripada analisis sensitiviti, (teknik ICT) berpotensi untuk aplikasi klinikal 
yang pelbagai. 
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DEVELOPMENT OF Mycobacterium tuberculosis 16 kDa PROTEIN 
DETECTION USING IMMUNOCHROMATOGRAPHY TEST 
 
ABSTRACT 
 
Mycobacterium tuberculosis (Mtb) is a pathogenic bacterium that can cause 
tuberculosis (TB). This contagious disease remains a severe health problem in the 
world. The disease is transmitted via inhalation of airborne droplets carrying Mtb 
from TB patients. Early detection of infection is vital to prevent transmission of the 
disease to people in close contact with the patients. To date, there is no simple, rapid, 
sensitive and specific diagnostic test for TB. Previous studies showed the potential of 
Mtb 16 kDa antigen in TB diagnosis. In this study, an immunochromatographic 
(ICT) lateral flow dipstick assay against 16 kDa antigen was developed and assessed 
as a potential rapid method to diagnose TB. A 16 kDa monoclonal antibody was 
optimized as the capturing and detection antibody on the ICT platform. The 
parameters of control line, blocking reagent, running buffer, conjugate and sample 
pad were also optimized before a complete prototype of TB-antigen ICT dipstick was 
developed. Sensitivity studies on TB-antigen ICT prototype dipstick showed that the 
dipstick was capable to detect purified 16 kDa antigen as low as 125 ng. However, 
the specificity of the assay was inconclusive probably due to the method used for 
sample preparation, which needs further study. The analytical sensitivity suggests its 
potential usefulness in different clinical applications. 
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CHAPTER 1 
LITERATURE REVIEW 
 
1.1 Background 
Tuberculosis (TB) is still a leading cause of mortality from infectious disease and 
remains a major global health problem worldwide. Even though the Bacillus 
Calmette–Guérin (BCG) vaccine and anti-TB drugs have been used for the past 90 
and 50 years respectively, the mortality rate caused by TB is still considerably high. 
The Stop TB Partnership revealed in its Global Plan To Stop TB 2011-2015 that one 
major challenge is to rapidly and effectively diagnose TB in an early stage of 
infection (WHO, 2010a). The development of rapid diagnostic tests is very crucial to 
initiate treatment and control of the disease. Previous studies conducted by Trilling et 
al. (2011), Siddiqui et. al (2011), Kaushik et. al (2012) and Srivastava et al. (2013) 
indicated that the 16 kDa protein has a potential role in TB diagnosis. In this study, 
the 16 kDa antigen was evaluated as a candidate marker for development of an 
immunodiagnostic test for the diagnosis of TB. Lateral flow 
immunochromatographic test (ICT) has been evaluated for the diagnosis of TB since 
it utilise a simple, rapid, inexpensive, sensitive and specific platform as previously 
reported by Said et. al (2011).  
1.2 History of Tuberculosis (TB) 
TB is an ancient illness. TB has been discovered in humans since antiquity. The 
archeological evidence of TB disease has been recognized in the fragments of the 
spinal columns of Egyptian mummies from 2400 BCE (Madkour, 2004). The history 
of TB is documented in ancient Babylonian, and Chinese writings. The term 
“phthisis” appear in Greek literature around 460 BCE. Hippocrates in his writing 
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identified and described phthisis as the most widespread disease that caused death 
(Palomino et al., 2007). Hippocrates defined phthisis as a chronic disease 
accompanied by productive cough, sweating, and fever. Later, the Greek physicians 
Aristotle (384-322 BC), and Galen (131-200 AD) stated TB as a transmissible 
disease reported (Kanai, 1990). 
In 1720, the English physician Benjamin Marten in his publication “A New Theory 
of Consumptions”, hypothesized that TB could be caused by “minute living 
creatures” as cited by Doetsch (1978). A further significant advance was observed in 
1865 when a French military physician, Jean-Antoine Villemin (1827-1892) 
indicated that TB is caused by a specific microorganism (cited in Daniel, 2006). 
Mycobacterium tuberculosis (Mtb) was finally identified by Robert Koch in 1882 
with a staining technique which gave birth to TB diagnostics (Koch, 1882, cited in 
Blevin and Bronze, 2010). This early bacteriologist’s work was first presented in 
Berlin on 24th March 1882 (Koch, 1882, cited in Daniel 2005, cited in Palomino, 
2007, WHO, 2009). Koch had created a guideline to determine the causative agents 
of several specific infectious diseases. This guideline was named as “Koch’s 
Postulates”. According to this guideline, bacterium suspected as a causative factor of 
a disease must exist in the infected tissue (such as blood) of an infected person or 
animal (Tortora et al., 2010). When the infected tissue was inoculated onto solid 
media, it must produce pure colonies and that must be infectious to experimental 
animals. Then, the bacteria must be retrieved as pure colonies from the second 
infected animal tissues (Palomino et al., 2007; Blevins and Bronze, 2010; Tortora et 
al., 2010). Lehmann and Newman then classified the microorganism as 
Mycobacterium genus that belongs to the Mycobacteriaceae family in 1896 (Grange, 
1980; Grange, 1985). 
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1.3 Global incidence of TB 
1.3.1 Epidemiology of TB 
World Health Organization (WHO) declared TB as a global emergency in 1993 with 
the need to implement immediate control measures (WHO, 1994). According to 
WHO (2012), TB remains a major global health problem and is responsible for 
millions of incident cases each year. TB was reported as the second leading cause of 
death from an infectious disease worldwide, after acquired immune deficiency 
syndrome (AIDS) which is caused by human immunodeficiency virus (HIV) (WHO, 
2012). 
According to Lange and Mori (2010), TB epidemics can be classified into high 
prevalence and low prevalence areas based on the extent of TB incidence. The low 
prevalence areas are composed of countries that experienced serious TB epidemics 
after the 18th century but the incidence rate have gradually and successfully reduced 
to 100 cases per 100 000 population or less. They are industrialized countries. On the 
other hand, the high prevalence areas are countries that have suffered TB epidemics 
after the 20th century with an incidence rate of more than 100 cases per 100 000 
population. These high prevalence areas mostly comprise developing countries.  
Global Tuberculosis Report 2013 reported that in 2012, there were an estimated 8.6 
million people who developed TB and 1.3 million deaths due to TB including 320 
000 who were HIV-positive. South –East Asia documented the highest cases 
worldwide in 2012 (29%) followed by African (27%) and Western Pacific regions 
(19%). The report also shows that the most populous countries of Asia such as India 
and China have the largest number of incidence with 26% and 12% of the total 
global cases respectively (WHO, 2013). 
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Globally, there are numerous challenges, such as multi drug resistant TB (MDR-TB), 
poor diagnosis of TB, TB infection among immigrants from high-prevalence areas, 
and co-infection with HIV (Frieden et al., 2003; Lange and Mori, 2010). Currently, it 
is estimated that about 1.1 million (13%) of the 8.6 million new TB patients in 2012 
were HIV infected and about 75% of these incident cases were from Africa (WHO, 
2013). WHO (2013) also reported that 450 000 people developed MDR-TB and there 
were an estimated 170 000 deaths from MDR-TB in 2012 with Eastern Europe and 
central Asia reporting the highest cases. Some countries have more than 20% of new 
TB cases with MDR-TB and more than 50% of those previously treated for TB have 
MDR-TB. 
However, the large number of TB incident cases started to decline around 2003 as a 
consequence of the global effort in TB control by the implementation of the Directly 
Observed Therapy Short-course (DOTS) strategy for TB care since 1990s (Lange 
and Mori, 2010; WHO, 2012; WHO, 2013).  
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Figure 1.1 Estimated number of new TB cases (all forms) 2012 worldwide (Adapted from WHO Tuberculosis Report, 2013). 
 6 
 
1.3.2 TB in Malaysia 
In the early 1940s and 1950s, TB was the leading cause of death in Malaysia 
(Iyawoo, 2004). However, since the National TB Control Programme (NTP) was 
launched in 1961, morbidity and mortality rates decreased rapidly. TB cases were 
successfully reduced in Malaysia, and Malaysia was categorized as a country with 
intermediate burden of TB (Mohamed Naim, 2004). Nevertheless, since 1995, new 
cases of TB increased and in 1998, TB was ranked 11
th
 among the top causes of 
death in Malaysia (Iyawoo, 2004; Mohamed Naim, 2004). The high prevalence of 
TB during 2000-2001 is probably due to the migration of foreign workers into 
Malaysia who originated from high prevalence TB countries. Approximately 10% of 
TB cases reported in Malaysia involved the immigrant population, 90% of whom are 
from the Philippines and Indonesia. These two countries have been classified as high 
burden countries of TB by WHO (Iyawoo, 2004). According to Atif et. al. (2012), 
TB incidence rates were around 82-85 cases of 100 000 population in 2007-2011. It 
was also reported that there were increases of new cases from 15000 cases (2002) up 
to 16665 (2006) and 20000 cases in 2011 (Rafiza et al., 2011; Atif et al., 2012; 
Ministry of Health, 2012a).  
Ministry of Health Malaysia (MOH) stated that there was a steady increase in TB 
cases from 2007 to 2011. In 2012, 22710 TB cases were recorded with 1520 deaths 
with a notification rate of 72 per 100,000 cases in 2011 and 78.7 per 100 000 cases in 
2012. The highest incidence was reported in Sabah with 4426 TB cases followed by 
Selangor (3560 cases) and Sarawak (2430). MOH also reported that foreigners 
contributed to the sudden surge of TB cases in Malaysia especially from higher TB 
burden countries (Benedict, 2014). 
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Figure 1.2 TB incidence according to states in Malaysia, 2007-2012. 
(The table was taken from Benedict (2014) [Online] Available from: http://www.themalaymailonline.com/malaysia/article/tb-kills-more-
annually-than-dengue-says-ministry#sthash.QZltWk92.dpuf)
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1.4 Mycobacterium tuberculosis (Mtb) 
1.4.1 Causative Agent 
Mtb and M. bovis species of Mtb complex (MTBC) infect humans and a wide variety 
of animal species (Kubica et al., 2006; Cleaveland et al., 2007). These microbial 
species are actually closely related to each other at the genomic and antigenic levels. 
M. bovis causes TB mainly in the bovine species. However, M. bovis can also infect 
humans especially through drinking infected milk (Collins et al., 1997; Ayele et al., 
2004; Kubica et al., 2006; Tortora et al., 2010). Mtb is identified as the etiologic 
agent of TB in humans and it is reported as one of the most devastating human 
pathogens in the world (Dietrich and Doherty, 2009; Gengenbacher and Kaufmann, 
2012). 
1.4.2 Features and Life Cycle 
Mtb is a bacterium belonging to the family of Mycobacteria (Mycobacteriaceae) 
(Brighenti and Lerm, 2012), a non-motile organism, that is slender or slightly curved 
rod shape bacterium distantly related to Actinomycytes. Many nonpathogenic 
mycobacteria are components of the normal flora of humans (Todar, 2012; Sharma et 
al., 2013). 
Mtb is 2-4 m in length and 0.2-0.5 m in breadth (Todar, 2012; Sharma et al., 
2013). Mtb has a lipid containing cell wall which is responsible for acid-fastness, 
namely when stained with carbol fuchsin dye and is resistant to decolorization by 
acid-alcohol. This characteristic is used in Ziehl-Neelsen staining. The lipid 
containing cell wall is also associated with the resistance of Mtb to environmental 
stresses such as drying and chemical antimicrobials (Tortora et al., 2010). Figure 1.3 
shows the image of Mtb bacillus under scanning electron micrograph. 
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Figure 1.3 Scanning electron micrograph of the Mtb bacillus. 
(The picture was adapted from Todar (2012) [Online]. Available from: 
http://textbookofbacteriology.net/tuberculosis.html). 
 
 
 
 
 
Figure 1.4 Composition of Mtb cell wall (Adapted from Riley, 2006). 
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The Mtb cell wall structure of Mtb consists of peptidoglycan, peptide side-chains, 
glycolipid and mycolic acids (Figure 1.4). The peptidoglycan forms the first layer or 
innermost layer of the Mtb cell wall, which is linked to the arabinogalactan layer and 
also to mycolic acids. Mycolic acids are strong hydrophobic molecules that form a 
special lipid barrier or shell around the organism and affect permeability properties at 
the cell surface (Brennan, 2003; Riley, 2006; Todar, 2012). 
Besides mycolic acids, other molecules such as lipoarabinomannan (LAM), 
lipomannan and 19 kDa lipoprotein are also associated with the cell wall of Mtb. 
These molecules are able to stimulate host immune responses (Riley, 2006). 
Mtb is an obligate aerobe. For this reason, in the classic case of TB, Mtb complexes 
are always found in the well-aerated upper lobes of the lungs. The bacterium is a 
facultative intracellular parasite of macrophages with a slow growth (15-20 hours or 
longer generation time), a physiological characteristic that may contribute to its 
virulence (Tortora et al., 2010; Gengenbacher and Kaufmann, 2012; Todar, 2012; 
Sharma et al., 2013). 
1.4.3 Genetics of Mtb 
The genome is defined as the whole set of genes within a cell (Ratledge and 
Stanford, 1982). The entire genome of Mtb H37Rv strain was published by Cole et 
al. (1998) with the complete deoxyribonucleic acid (DNA) sequence and annotation 
(Figure 1.5). The genetics of Mtb was subsequently studied extensively by Smith 
(2003). 
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Figure 1.5 Circular map of the chromosome of Mtb H37Rv. 
(The picture was adapted from Cole et al. (1998), Deciphering the biology of 
Mycobacterium tuberculosis from the complete genome sequence. Nature, 
393(6685), 537-44.) 
 
 
 
Figure 1.6 TB is spread from person to person through the air. The dots in the air 
represent droplet nuclei containing germs (Mtb). 
 
(The picture was adapted from CDC (2012) [Online]. Available from : 
http://www.cdc.gov/TB/TOPIC/basics/default.htm) 
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According to Smith (2003), the size of a Mtb H37Rv genome is 4.4 X 10
6
 bp which 
consists of approximately 4000 genes. The genome of Mtb has several unique 
characteristics compared to other bacterium. Mtb has more than 200 genes involved 
in the metabolism of fatty acids. These various fatty acid enzymes genes are 
probably associated with the ability of this organism to grow within macrophages 
where fatty acid is the major carbon source. Mtb genome also contains PE and PPE 
genes which encode for PE (Pro-Glu) and PPE (Pro-Pro-Glu) proteins located in 2 
conserved locations in the N-terminal region of these protein families. These proteins 
may be involved in virulence and antigenicity of mycobacteria. 
1.4.4 Transmission of TB 
TB disease is spread by small airborne droplets (particles 1 to 5 m in diameter) 
called droplet nuclei. A person with active TB can generate or produce TB germs 
(Mtb) in the lungs or throat. Those germs are expelled into the air via aerosol by 
coughing, sneezing, talking or singing (Figure 1.6). The germs (in droplet nuclei) can 
remain airborne for minutes to hours after expectoration (CDC, 2000; Knechel, 2009; 
Ahmad, 2011). The number of bacilli in the droplets, the virulence of the bacilli, 
exposure of the bacilli to UV light, degree of ventilation, and occasions for 
aerosolization all influence transmission (CDC, 2000). Only people who 
subsequently breathe these germs into their lungs may become infected (CDC, 2012; 
Colin, 2014). Those who breathe in tuberculosis germs usually have had very close 
contact with someone who has the disease (CDC, 2011). Introduction of Mtb into the 
lungs leads to infection of the respiratory system. However, Mtb can also spread and 
infect other organs and cause extrapulmonary TB (Knechel, 2009). 
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1.4.5 Pathophysiology of TB 
Studies showed that TB is spread through small or large water droplets containing a 
single or a few viable bacilli during coughing, sneezing, talking or singing from 
active TB patients (Palomino et al., 2007). Everybody within the surrounding area 
can be exposed to the droplets. TB is most commonly acquired when an individual is 
exposed and inhales droplets containing the viable bacilli (Mtb) (Tortora et al., 
2010). After inhalation of tubercle bacilli, the bacilli will enter the alveolar spaces in 
the lungs which will then be ingested by alveolar macrophages and dendritic cells 
(van Crevel et al., 2002). 
Alveolar macrophages act as the first line of defence against Mtb which can destroy 
tubercle bacilli. However the destruction of tubercle bacilli depends not only on the 
microbicidal activity of the alveolar macrophages because the virulence of the 
tubercle bacilli has an important role in this process too (van Crevel et al., 2002). If 
the bacteria survive from the destructive machinery of alveolar macrophages, they 
will multiply slowly (dividing approximately 25 to 32 hr) within the alveolar 
macrophages which cause the weakening and disruption of the macrophages (CDC, 
2000). The disruption of infected alveolar macrophages will attract blood monocytes 
and other inflammatory cells to the lungs. In the lungs, the blood monocytes will 
develop into macrophages and readily take in the tubercle bacilli. However the 
blood-derived macrophages will be unable to destroy the tubercle bacilli (van Crevel 
et al., 2002). The ingested tubercle bacilli will multiply within the blood-derived 
macrophages and produce mycobacterial foci in the lungs (Kaufmann, 2004).  
While the infected alveolar macrophages remain in the lung tissues, some of the 
infected dendritic cells will migrate to the draining lymph nodes. In the draining 
lymph nodes, T cells will be activated and after migration, T cells recognize the 
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mycobacterial foci in the lung (Kaufmann, 2001). The activated T cells together with 
macrophages will form a surrounding layer at the infection foci site. Then the 
surrounding layer will become a lump (granuloma) or walled-off lesion called 
tubercle. After several weeks, the interior part of the tubercle will become caseous 
(cheese-like appearance) (Gonzalez-Juarrero et al., 2001; Tortora et al., 2010; 
Ahmad, 2011). This caseous lesion will inhibit the highly aerobic Mtb from 
receiving air supply. Accordingly, the growth of Mtb will be restricted and TB 
infection becomes stationary or dormant until months or even years (van Crevel et 
al., 2002). This condition is also known as latent TB infection (LTBI).  
However, a few patients (with primary infection) may develop active TB disease 
which will progress rapidly into active pulmonary, extrapulmonary or disseminated 
disease. Persons susceptible to such a rapid course include those who have 
compromised immune systems (such as HIV/AIDS patients), children and the elderly 
(McKinley Health Center, 2008; CDC, 2012). TB disease which develops soon (after 
infection), seen as initial infection (primary infection) without previous natural 
contact with Mtb is called primary TB (Palomino et al., 2007). Symptoms of primary 
TB are generally mild and include low-grade fever (Poulsen, 1950; Poulsen, 1957). 
However, most of persons with primary pulmonary TB remain asymptomatic 
(Hoffmann and Churchyard, 2009; Knechel, 2009). 
Sometimes, the caseous lesion may become larger and more liquid. This process is 
called liquefaction. The liquefied lesion will become air filled and provide an aerobic 
condition within the lesion (Tortora et al., 2010). This aerobic condition favours the 
growth of tubercle bacilli within the liquefied lesion. At this time point, Mtb will rise 
from dormancy and multiply extensively within and/or outside of the infected 
macrophages (Figure 1.7). 
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Figure 1.7 The pathogenesis of tuberculosis. This figure represents the 
progression of the disease when the defenses of the body fail. The 
picture was adopted from Tortora et al. (2010). 
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The liquefied lesion may rupture into the bronchioles spreading tubercle bacilli to 
other parts of the lung and body systems (van Crevel et al., 2002; Tortora et al., 
2010). The progression of TB after a period of LTBI is called secondary TB. 
Secondary TB is also known as post-primary or reactivation TB. Common symptoms 
of secondary TB include cough, fever, fatigue, night sweats, anorexia, weight loss, 
and malaise (Hoffmann and Churchyard, 2009; Knechel, 2009; Sia and Wieland, 
2011; Delong, 2013). 
 
1.5 Immunity against TB 
1.5.1 General View of Immune System in Human 
Our environment contains various pathogens such as viruses, bacteria, protozoa, 
fungi and parasites. These pathogens are able to infect and cause diseases in humans. 
In normal individuals, most infections are short-lived and cause little permanent 
damage (Roitt et al., 2001; Roitt et al., 2006). The human immune system recognizes 
foreign agents and develop an immune response against these agents in order to 
eliminate them. There are two types of immune responses known as innate and 
adaptive immune response (Abbas and Lichtman, 2004; Abbas et al., 2010). The 
innate immune response mediates an early immune reaction against microbes, 
follows by adaptive immune response (Abbas et al., 2010). This early response 
involves several components of defence, including cytokine production, 
phagocytosis by phagocytes (macrophages and neutrophils), complement system and 
also physical and chemical barriers (Abbas et al., 2010). In contrast, adaptive 
immune responses involves specific recognition systems mediated by T and B 
lymphocytes. Adaptive immune response is able to produce long lasting immunity 
against a specific pathogen upon activation. Thus, adaptive immune response 
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provides specificity and memory against previously encountered pathogens (Roitt et 
al., 2006). 
1.5.2 Innate Immune Responses against TB 
Mtb is an air-borne microorganism, which infects primary lung tissues. The 
inhalation of Mtb into the alveolar space will activates the alveolar resident 
macrophages, the cell type involved in the phagocytosis (Smith, 2003; Palomino et 
al., 2007; Kleinnijenhuis et al., 2011). The phagocytosis of Mtb by resident 
macrophages is mediated by various receptors expressed on their surface (Palomino 
et al., 2007; Dheda et al., 2010). 
Recognition of Mtb antigens by the immune system is an important step to achieve 
an effective protective response against these pathogens. Mtb antigens such as LAM, 
lipoproteins and Mtb DNA are recognized by a set of receptors called as Toll-like 
receptors (TLRs) (Smith, 2003; Roitt et al., 2006). TLRs are found on the surface of 
macrophages and dendritic cells (Roitt et al., 2006; Palomino et al., 2007; 
Kleinnijenhuis et al., 2011). TLRs play a central role in immune recognition of Mtb. 
The interaction of TLRs with Mtb activates nuclear factor kB of signalling pathways 
(NF-kB), causing secretion of pro-inflammatory cytokines (such as TNF- , IL-6, IL-
12, IL-18 and IFN- ), chemokines. This will promote phagocytosis and killing of the 
Mtb, and antigen presentation by macrophages (Dheda et al., 2010; Kleinnijenhuis et 
al., 2011). The processed Mtb antigen is further eliminated by T and B cells of 
adaptive immune response following antigen-presentation by activated macrophages 
(Roitt et al., 2006). 
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1.5.3 Adaptive Immunity against Mtb 
Adaptive immune response against Mtb begins with three processes of antigen 
presentation, co-stimulation and cytokine production (van Crevel et al., 2002). 
Mycobacterial antigen presentation by antigen presenting cell (APC) to T-cells 
involves three distinct mechanisms. The first mechanism involves extracellular 
antigen presentation by APC to CD4
+
 T-cells via major histocompatibility complex 
(MHC) class II molecules. The second mechanism involves intracellular antigen 
presentation by APC to CD8
+
 T-cells via MHC class I molecules. The third 
mechanism involves the presentation of mycobacterial antigens through Type 1 CD1 
(-a, -b, and -c) molecules on the APC to CD1 restricted T cells. CD1 molecules is a 
non-polymorphic MHC class I molecule expressed on the surface of APC which is 
able to recognize mycobacterial lipoprotein (van Crevel et al., 2002).  
T-cell activation requires cytokines produced by activated macrophages and dendritic 
cells. Both cells are capable of producing Type 1 cytokines IL-12, IL-18 and IL-23 
(Oppmann et al., 2000). T-cell activation may be decreased or delayed if the Type 1 
cytokine production is reduced (van Crevel et al., 2002). 
Cytokines including IL-12, IL-23, IL-7, IL-15 and TNF-  are released from the 
infected macrophages and dendritic cells. The effector cytokine, IFN-  is later 
secreted by these T-cells together with TNF-  which in turn activates macrophages 
that kill intracellular mycobacteria by reactive oxygen and nitrogen immediates 
(Dheda et al., 2010). 
1.6 Control of Mtb Infection 
WHO has recommended the DOTS to control Mtb infection in mid-1990s. DOTS 
strategy includes political commitment, initial diagnosis by sputum-smear 
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microscopy, short-course treatment, continuous drug supply and systematic 
monitoring for every patient that started on treatment (Frieden and Driver, 2003). To 
date, DOTS remains as core elements of the Stop TB strategy (WHO, 2013). 
According to the Global TB Control Report 2013, a cumulative total of 56 million 
TB patients were successfully treated in DOTS programmes between 1995 and 2012. 
Thus, up to 22 million lives were saved including women and children (WHO, 
2013). In Malaysia, Clinical Practise Guidelines (CPG) was introduced by the MOH 
to assist clinicians and other healthcare providers in making evidence-based 
decisions on appropriate management and treatment of TB (Ministry of Health, 
2012b). 
1.6.1  Therapy and Anti-TB Drug Treatment 
Anti-TB drug treatment was started in 1944 after the discovery of streptomycin and 
para aminosalicylic acid (Shatz et al., 1944; Lehmann, 1964; Iseman, 2002; cited in 
Palomino, 2007). Currently, more than 10 anti-TB drugs are available for the 
treatment of TB. The most frequently used are Isoniazid, Kanamycin, Pyrazinamide, 
Ethambutol and Rifampicin. According to Onyebujoh et al. (2005), there are 2 main 
objectives of anti-TB treatment, to kill Mtb living extracellularly in lung cavities and 
to achieve complete sterilization and elimination of Mtb intracelullarly. Generally, 
the mechanisms of action for these anti-TB drugs are by killing or inhibiting the 
growth of Mtb. The recommended treatment consists of 6 months regimens with 2 
phases. TB patients are treated with Isoniazid, Rifampicin, Pyrazinamide and either 
Ethambutol or Streptomycin for the first 2 months intensive phase treatment follow 
by continuation phase using Isoniazid and Rifampicin for the remaining 4 months 
(Iyawoo, 2004). 
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1.6.2  BCG Vaccination  
To date, the almost one-century old BCG vaccine remains as the only available 
vaccine against TB and is widely administered worldwide (Luca and Mihaescu, 
2013). Calmette and Guerin developed the BCG vaccine which consists of a live 
attenuated strain derived from M. bovis in 1908-1920 (at Pasteur Institute in Lille). 
The BCG was then administrated to humans during the 1920s and showed high 
protective efficacy against TB infection (Sakula, 1983). 
1.7 TB Diagnosis 
1.7.1 Conventional Methods 
1.7.1.1 Microscopy 
Direct sputum smear microscopy is the main conventional technique used in most 
diagnostic laboratories for decades (WHO, 2010c; UNITAID, 2012). The method of 
choice is Ziehl-Neelsen staining but fluorescent acid-fast staining has also been used 
(Toman, 2004b). The Ziehl-Neelsen method still remains the mainstay of point of 
care (POC) diagnosis in most TB endemic countries (Dheda et al., 2013). 
According to Laszlo (1999), this method is rapid and has great value especially in the 
detection of active infectious cases. However, it has limited sensitivity, requiring at 
least 10
5 
bacilli per millilitre of specimen for positive detection (Toman, 2004a). 
Moreover it cannot distinguish Mtb from other non-tuberculous mycobacteria (NTM) 
(Hobby et al., 1973; WHO, 2010b). In addition, this technique is also ineffective for 
the diagnosis of extra-pulmonary TB and requires well-trained and motivated 
technicians (WHO, 2006; UNITAID, 2012). 
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1.7.1.2 Culture 
Active TB infection is defined when the organism is isolated from specimens using 
microbiological culture. The culture method remains as the diagnostic “gold 
standard” for both diagnosis and drug sensitivity testing (DST) of TB (Laszlo, 1999; 
Guillerm et al., 2006; WHO, 2011a). This technique can identify the Mtb organism 
in over 80% of TB cases with a specificity of over 98% (WHO, 2006). The 
sensitivity of culture is much higher than microscopy, requiring just 10 to 100 bacilli 
per millilitre of specimen (Laszlo, 1999). The most commonly used solid media in 
the laboratory are egg-based media (Lowenstein Jensen (LJ), Ogawa) and the agar-
based growth medium (Middlebrook 7H10, 7H11) (Guillerm et al., 2006; Palomino 
et al., 2007). However, this conventional method takes 2 to 6 weeks to obtain culture 
results and requires highly trained personnel (WHO, 2006). New rapid commercial 
techniques based on liquid and broth growth systems such as BACTEC 460TB, 
BACTEC MGIT
 
960, MB/BacT, SeptiChek-AFB, ESP Culture II System and many 
others were introduced in order to improve the detection time as well as to increase 
recovery. Many laboratories reported an average time for detection of 1 to 4 weeks 
using these systems (Rom and Garay, 2004; WHO, 2006; Anochie et al., 2012). 
Although the broth or liquid based growth systems are much better than conventional 
culture in terms of sensitivity and time of detection, it still has limitations because 
they require much higher capital and operating cost (Guillerm et al., 2006; WHO, 
2006). Furthermore, the only well-established rapid method for detecting 
mycobacteria in clinical specimens is the BACTEC 460TB system. However this 
method uses a radioactive component, thus introduces concerns related with waste 
disposal (Laszlo, 1999). 
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Recently, new rapid non-commercial microcolony culture based methods of 
Microscopic Observation Drug Susceptibility (MODS) and Thin Layer Agar (TLA) 
have been reported (Guillerm et al., 2006). Both methods appear to be rapid, 
inexpensive and accurate tools for active TB detection. However, a systematic 
review on both methods reported that they did not find sufficient evidence on the 
feasibility and costs of implementation, nor on the impact of these methods on 
patient outcomes (Leung et al., 2012). Other than that, both methods require well-
trained personnel and appropriate containment facilities. 
1.7.1.3 Biochemical tests 
A battery of biochemical tests are used for the identification of mycobacteria (Rom 
and Garay, 2004). According to Babady and Wengenack (2012), there are several 
well-standardized techniques of conventional biochemical tests. These include niacin 
accumulation, nitrate reduction, detection of pyrazinamidase, activity inhibition of 
thiophene-2-carboxylic acid hydrazide (T2H), iron uptake, urease production, 
catalase test, Tween 80 hydrolysis, tellurite reduction, and many others. Although 
these conventional biochemical assays are relatively inexpensive and simple to 
perform, they still have limitations especially due to the fact that the test can only be 
performed after primary culture are successful (which already requires incubation 
periods of up to 4 weeks) resulting in major delays in identification. 
1.7.1.4 Radioghraphy 
Chest radiography is fast, convenient and used widely for the detection of pulmonary 
TB. This method is sensitive in the diagnosis of pulmonary TB but of low specificity, 
especially in HIV infected patients (WHO, 2009). The conventional chest X-ray is 
the most common used radioghraphic method for screening, diagnosis, and treatment 
response follow-up in pulmonary TB cases. The more sensitive method to use is 
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chest computed tomography (CT), especially the high resolution CT, as it is able to 
detect early parenchymal lesions or enlargement of mediastinal lymph nodes and in 
determination of disease activity in TB (Lange and Mori, 2010). This technique 
could be useful and may be cost-effective for the management of patients. However 
the main drawback is its nonspecificity, resulting in over diagnosis when used alone. 
Furthermore, the whole capital and operational cost are considered highly expensive 
(WHO, 2006; Lange and Mori, 2010). 
1.7.2 Nucleic Acid Amplification Test (NAAT) 
The NAAT for the diagnosis of TB or to detect drug resistance is a sensitive method 
that can produce a much faster result than conventional culture methods (Dheda et 
al., 2013). The most common amplification techniques widely used are polymerase 
chain reaction (PCR), strand displacement amplification (SDA) and transcription 
mediated amplification (TMA) (WHO, 2006). PCR was originally described by 
Mullis and Faloona in 1987. PCR is a nucleic acid based technique that uses 
oligonucleotide primers to amplify specific DNA target sequences. DNA is amplified 
by repeated cycles of DNA denaturation, annealing of primer to the DNA and primer 
extension (Guatelli et al., 1989). Because of specificity of the designed primers, PCR 
has become a powerful means to detect small numbers of bacterial DNA present in 
clinical specimens. In comparison to PCR, SDA is an isothermal amplification of 
DNA sequence. It is based on the ability of a Hincll restriction enzyme to nick a 
hemi-modified recognition site and the ability of a polymerase to displace a 
downstream DNA strand during replication (Down et al., 1996; Roth et al., 1997). 
TMA is also an isothermal process that can amplify DNA and Ribonucleic acid 
(RNA) targets to a billion fold in less than 1 hour’s time. The method employs 2 
enzymes to perform the reaction which consists of RNA polymerase and reverse 
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transcriptase. The entire reaction is performed in a water bath at the same 
temperature. Thus, this technique also does not require a thermal cycler to perform 
the test (Roka Bioscience, 2013). 
According to Dheda et al. (2013), there are several commercially available NAAT 
techniques for TB diagnosis from a few companies. These includes (i) PCR based 
NAAT; Amplicor MTB, Cobas Amplicor, and LightCycler Mycobacterium 
Detection kits (Roche, USA); Genotype MTBDRplus and GenotypeMTBDRsl (Hain 
Lifescience, Germany), INNO-LiPA Rif TB line probe assays (Innogenetics, 
Belgium); and Xpert MTB/RIF nested real-time PCR assay (Cepheid), (ii) SDA 
based; BD-ProbeTec-ET (Becton Dickinson, USA), (iii) TMA based; Amplified M. 
tuberculosis Direct (AMTD) (Gen-probe, USA). The Amplicor MTB test (Roche, 
USA) and AMTD test (Gen-probe, USA) techniques have been approved by the 
United States Food and Drug Administration (FDA) for use in Mtb detection 
procedure (Babady and Wengenack, 2012; UNITAID, 2012; Delong, 2013; Sharma 
et al., 2013). In general, the application of NAAT has created some very sensitive 
and specific diagnostic tools for TB. The principal advantages of NAAT is that a 
result can be obtained in only a few hours and the test process can be adapted for 
high- or low-throughput screening depending upon demand. However, these 
techniques require well-trained personnel to perform the test. In addition, due the 
cost of the instrument and high operational cost, this technique is not feasible to be 
used in many low income setting areas (WHO, 2006). 
1.7.3 Immunological Tests 
1.7.3.1 Tuberculin Skin Test (TST) 
TST is the method used for screening suspected TB patients since 1930s (MMWR, 
1982; Rossman and MacGregor, 1995; CDC, 2003). Several methods were 
